Abstract | BACKGROUND: OBJECTIVE: We reviewed results obtained in all clinical trials reported thus far employing anti-EBV adoptive immunotherapy for different virus-related malignancies. METHODS: 'PTLD after HSCT', 'PTLD after SOT', 'NPC', 'HD', 'SCAEBV' and ' extranodal NK/T cell lymphoma', in combination with 'Adoptive immunotherapy' and 'Adoptive transfer', were used as search keys for papers in PubMed. CONCLUSIONS: Although the heterogeneity of different studies precludes their collection for a meta-analysis, it can be inferred that adoptive therapy with EBV-specific CTL is safe, well tolerated and particularly effective in the case of most immunogenic tumors, like post-transplant lymphoproliferative disease.
|
Authors | Anna Merlo, Riccardo Turrini, Riccardo Dolcetti, Paola Zanovello, Alberto Amadori, Antonio Rosato |
Journal | Expert opinion on biological therapy
(Expert Opin Biol Ther)
Vol. 8
Issue 9
Pg. 1265-94
(Sep 2008)
ISSN: 1744-7682 [Electronic] England |
PMID | 18694349
(Publication Type: Journal Article, Research Support, Non-U.S. Gov't, Review)
|
Topics |
- Adoptive Transfer
- Burkitt Lymphoma
(therapy, virology)
- Data Collection
- Hematopoietic Stem Cell Transplantation
- Herpesvirus 4, Human
(isolation & purification)
- Hodgkin Disease
(therapy, virology)
- Humans
- Lymphoproliferative Disorders
(therapy, virology)
- Nasopharyngeal Neoplasms
(therapy, virology)
|